
    
      -  In the treatment group, participants will receive methotrexate 15mg by mouth/week with
           optional for increase up to 20mg/week in non-responders and folic acid 1mg by mouth
           daily for six months in Phase I.

        -  In the control group, participants will receive placebo methotrexate tablets by
           mouth/week with faux increase optional in non-responders and folic acid 1mg by mouth
           daily for six months in Phase I.

        -  In Phase II, any patient may elect to stop taking the study drug or transition to open
           label active treatment group for the following six months.
    
  